TY - JOUR
T1 - A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing
AU - Kyker-Snowman, Kelly
AU - Erlanger Avigdor, Bracha
AU - Nasim, Mansoor
AU - Cimino-Mathews, Ashley
AU - Wheelan, Sarah J.
AU - Argani, Pedram
AU - Park, Ben Ho
N1 - Funding Information:
lan lab for helpful thoughts and discussions. This work was supported by NIH R01CA194024, NIH P30CA006973, Susan G. Komen, the Commonwealth Foundation, the Breast Cancer Research Foundation, the Marcie Ellen Foundation, The Helen Golde Trust, and The Can-ney Foundation. None of the funding sources influenced the design, interpretation or submission of this manuscript.
Funding Information:
We thank various members of the Park and Wheelan lab for helpful thoughts and discussions. This work was supported by NIH R01CA194024, NIH P30CA006973, Susan G. Komen, the Commonwealth Foundation, the Breast Cancer Research Foundation, the Marcie Ellen Foundation, The Helen Golde Trust, and The Canney Foundation. None of the funding sources influenced the design, interpretation or submission of this manuscript. B.H.P. is a paid member of scientific advisory boards for Loxo Oncology, and has ownership interest in Loxo Oncology. B.H.P. has research contracts with Foundation Medicine, Inc. Under separate licensing agreements between Horizon Discovery, LTD and The Johns Hopkins University, B.H.P. is entitled to a share of royalties received by the University on sales of products. The terms of this arrangement are being managed by the Johns Hopkins University, in accordance with its conflict of interest policies. No potential conflicts of interest were disclosed by the other authors.
Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Background/purpose: Tumor heterogeneity is a now well-recognized phenomenon that can affect the classification, prognosis and treatment of human cancers. Heterogeneity is often described in primary breast cancers based upon histologic subtypes, hormone- and HER2-receptor status, and immunolabeling for various markers, which can be seen within a single tumor as mixed cellular populations, or as separate discrete foci. Experimental design/methods: Here, we present a case report of a patient’s primary breast cancer that had two separate but adjacent histologic components, one that was estrogen receptor (ER) positive, and the other ER negative. Each component was subjected to whole exome sequencing and compared for gene identity to determine clonal origin. Results: Using prior bioinformatic tools, we demonstrated that both the ER positive and negative components shared many variants, including passenger and driver alterations. Copy number variations also supported the two components were derived from a single common clone. Conclusions: These analyses strongly suggest that the two ER components of this patient’s breast cancer were derived from the same clonal origin. Our results have implications for the evolution of breast cancers with mixed histologies, and how they might be best managed for optimal therapy.
AB - Background/purpose: Tumor heterogeneity is a now well-recognized phenomenon that can affect the classification, prognosis and treatment of human cancers. Heterogeneity is often described in primary breast cancers based upon histologic subtypes, hormone- and HER2-receptor status, and immunolabeling for various markers, which can be seen within a single tumor as mixed cellular populations, or as separate discrete foci. Experimental design/methods: Here, we present a case report of a patient’s primary breast cancer that had two separate but adjacent histologic components, one that was estrogen receptor (ER) positive, and the other ER negative. Each component was subjected to whole exome sequencing and compared for gene identity to determine clonal origin. Results: Using prior bioinformatic tools, we demonstrated that both the ER positive and negative components shared many variants, including passenger and driver alterations. Copy number variations also supported the two components were derived from a single common clone. Conclusions: These analyses strongly suggest that the two ER components of this patient’s breast cancer were derived from the same clonal origin. Our results have implications for the evolution of breast cancers with mixed histologies, and how they might be best managed for optimal therapy.
KW - Breast cancer
KW - Estrogen receptor
KW - Whole exome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85043711219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043711219&partnerID=8YFLogxK
U2 - 10.1007/s10549-018-4742-x
DO - 10.1007/s10549-018-4742-x
M3 - Article
C2 - 29541976
AN - SCOPUS:85043711219
SN - 0167-6806
VL - 170
SP - 425
EP - 430
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -